drugset / Trial / NCT01823978
Safety Study of BPX-201 Dendritic Cell Vaccine Plus AP1903 in Metastatic Castrate Resistent Prostate Cancer
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase I, non-randomized, dose escalation study of the safety, biomarkers, and preliminary efficacy of dendritic cell vaccine, BPX-201, plus activating agent, AP1903, in patients with metastatic castrate resistant prostate cancer.
Timeline
- Start
- 2013-04
- Primary completion
- 2016-05
- Completion
- 2017-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BPX-201 | Vaccine | 1e+07 cells | Other |
| Subject | BPX-201 | Vaccine | 2e+07 cells | Other |
| Subject | BPX-201 | Vaccine | 4e+07 cells | Other |
| Background | Rimiducid | Other / unclassified | 40 mg | Intravenous |